Apoptosis and cell proliferation: Correlation with BCL-2 and P53 oncoprotein expression in human hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 61, Issue 133, 2014, Pages 1393-1401

  El Emshaty, Hoda M ^a   Saad, Entsar A ^b   Toson, Elshahat A ^b   Abdel Malak, Camelia A ^b   Gadelhak, Nabil A ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Bcl 2; ELISA; HCC; IHC; P53 Ag

Indexed keywords

ALPHA FETOPROTEIN; PROTEIN BCL 2; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UPREGULATION; BLOOD; CASE CONTROL STUDY; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LINEAR MODELS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84906968716     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge13453     Document Type: Article

References (49)

1. Tinke CL, Haas-Kogan D: Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics: Targets and Therapy 2012; 6: 207-219.
2. Kang YH, Park M-Y, Yoon D-Y, et al.: Dysregulation of overexpressed IL-32α in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-κB and Bcl-2. Cancer letters 2012; 318:226-233.
3. Morris SM, Baek JY, Koszarek A, et al.: TGF-β signaling promotes hepatocarcinogenesis induced by p53 loss. Hepatology 2012; 55(1):121-131.
4. Martin J, Dufour JF: Tumor suppressor and hepatocellular carcinoma. World J Gastroenterol 2008; 14:1720-1733. [PubMed: 18350603]. (Pubitemid 351493378)
5. Pang RW, Joh JW, Johnson PJ, et al.: Biology of hepatocellular carcinoma. Ann Surg Oncol. 2008; 15:962-971 [PubMed: 18236113].
6. Shin S, Sung BJ, Cho YS, et al.: An anti-apoptotic protein human surviving is a direct inhibitor of caspase-3 and -7. Biochemistry 2001; 40:1117-1123. (Pubitemid 32108606)
7. Stewart BW: Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J Natl Inst 1994; 86:1286-1296.
8. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80:293-299.
9. Ozaki T, Nakagawara A: P53: The attractive tumor suppressor in the cancer research field. Journal of Biomedicine and Biotechnology 2011; Article ID 603925, 13 pages.
10. Inoue K, Kurabayashi A, Shuin T, Ohtsuki Y, Furihata M: Overexpression of p53 protein in human tumors. Med Mol Morphol 2012; 45:115-123.
11. Hengartner MO: The biochemistry of apoptosis. Nature 2000; 407:770-776.
12. Zinkel S, Gross A, Yang E: Bcl-2 family in DNA damage and cell cycle control. Cell Death Differ 2006; 13:1351-1359. (Pubitemid 44057470)
13. Walensky LD: Bcl-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ 2006; 13:1339-1350.
14. Croker J, Boldy DAR, Egan MJ: How should we count AgNORs? Proposal for a standardized approach. J. Pathol. 1989; 158:185-188. (Pubitemid 19185434)
15. Hall PA, Lane DP: p53 in tumor pathology: Can we trust immunohistochemistry?. Revisted J. Pathol. 1994; 172:1-4. (Pubitemid 24074994)
16. Engvall E, Perlman P: Enzyme-Linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunohistochemistry 1971; 8:871-874.
17. Fabregat I: Dysregulation of apoptosis in hepatocellular carcinoma cells. Wold J Gastroenterol 2009; 15(5):513-520.
18. Kalogeraki A, Garbagnati F, Santinami M, Zoras O: DNA fragmentation and cell proliferation correlated with tumor grade in patients with hepatocellular carcinoma. Cancer 2002; 96(5): 301-305. (Pubitemid 35221618)
19. Nakajima T, Kagawa K, Ueda K, et al.: Evaluation of hepatic proliferative activity in chronic liver diseases and hepatocellular carcinomas by proliferating cell nuclear antigen (PCNA) immunohistochemical staining of methanol-fixed tissues. J Gastroenterol. 1994; 29(4): 450-454. (Pubitemid 24262713)
20. Nakopoulou L, Janinis J, Giannopolou I, et al.: Immunohistochemical expression of p53 protein and proliferating cell nuclear antigen in hepatocellular carcinoma. Pathol. Res. Pract. 1995; 191(12): 1208-1213. (Pubitemid 26060403)
21. Park YN, Chae KJ, Kim YB, Park C, Theise N: Apoptosis and proliferation in hepatocarcinogenesis related to cirrhosis. Cancer 2001; 92(11): 2733-2738. (Pubitemid 33091908)
22. Zhao M, Zimmermann A: Apoptosis in human hepatocellular carcinoma and in liver cell dysplasia is correlated with p53 protein immunoreactivity. J Cli Pathol. 1997; 50(5):394-400. (Pubitemid 27278443)
23. Lee YC, Wu WJ, Li WM, et al.: Prognostic value of p53 protein overexpression in upper tract urothelial carcinomas in Taiwan. Anticancer Res 2013; 33(3):1091-1098.
24. Luo JC, Neugut AI, Garbowski G, Forde KA, Treat M, Smith S: Levels of p53 antigen in the plasma of patients with adenomas and carcinomas of the colon. Cancer Lett. 1995; 91:235-240.
25. Cengiz C, Akarca US, Goker E, Yuce G: Detection of mutant p53 in hepatocellular cancer from turkey and its correlation with clinicopathologic parameters. Dig Dis. Sci. 2003; 48(5): 865-869. (Pubitemid 36470203)
26. Lim S-O, Park YM, Kim HS, et al.: Notch1 differentially regulates oncogenesis by wild type p53 overexpression and p53 mutation in grade III hepatocellular carcinoma. Hepatology 2011; 53:1352-1362.
27. Harris CC, Hollstein M: Clinical implications of the p53 tumor suppressor gene. New Engl. J. Med. 1993; 329:1318-1327. (Pubitemid 23317333)
28. Paiva C, Oshima CT, Lanzoni VP, Forones NM: Apoptosis, PCNA and p53 in hepatocellular carcinoma. Hepatogastroenterology 2002; 49(46): 1058-1061. (Pubitemid 34809786)
29. Beerheide W, Tan YJ, Teng E, et al.: Downregulation of proapoptotic proteins Bax and Bcl-X(S) in p53 overexpression hepatocellular carcinomas. Biochem. Biophys. Res. Commun.2000; 273(1):54-61. (Pubitemid 30426862)
30. Mitselou A, Karapiperides D, Nesseris I, Vougiouklakis T, Agnantis NJ: Altered expression of cell cycle and apoptotic proteins in human liver pathologies. Anticancer Research 2010; 30:4493-4502.
31. Yahagi N, Shimano H, Matsuzaka T, et al.: P53 involvement in the pathogenesis of fatty liver disease. J Bio Chem. 2004; 279:20571-20575. (Pubitemid 38656450)
32. Shiota G, Ishida M, Noguchi N, et al.: Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival. Dig. Dis. Sci. 2000; 45(1):122-128. (Pubitemid 30111698)
33. Royds JA, Iacopetta B: P53 and disease: when the guardian angel fails. Cell death Differ 2006; 13:1017-1026.
34. Brosh R, Rotter V: When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9(10):701-713.
35. D'Errico A, Grigioni WF, Fiorentino M, et al.: Overexpression of p53 protein and Ki67 proliferative index in hepatocellular carcinoma: an immunohistochemical study on 109 Italian patients. Pathol. Int. 1994; 44(9):682-687. (Pubitemid 24279800)
36. Suwa H, Ohisho G, Okada N, et al.: Clinical significance of serum p53 antigen in patients with pancreatic carcinomas. Gut 1997; 40: 647-653. (Pubitemid 27278334)
37. Volkmann M, Hofmann WJ, Muller M, et al.: Overexpression is frequent in European hepatocellular carcinoma and largely than of the codon 249 hot spot mutations. Oncogene 1994; 9:195-205.
38. Soung YH, Lee JW, Kim SY, et al.: CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res 2005; 65:815-821.
39. Koga H, Sakisaka S, Ohishi M, Sata M, Tanikawa K: Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 1997; 25:1077-1084. (Pubitemid 27199930)
40. Nathan B, Dyer AM, Ebbs SR, Jayatilake H, Gusterson BA: Expression of Bcl-2 like immunoreactivity in the normal breast and in breast cancer. The breast 1993; 2:134-137. (Pubitemid 24082163)
41. Bhatavdekar JM, Patel DD, Shah NG, et al.: Prognostic significance of immunohistochemically localized markers in stage II and stage III breast cancer: a multivariate analysis. Am. Sur. Oncol. 2000; 7(4): 305-311. (Pubitemid 30318320)
42. Garcia EJ, Lawson D, Cotsonis G, Cohen C: Hepatocellular carcinoma and markers of apoptosis (Bcl-2, BAX, BCL-X): Prognostic significance. Appl Immunohistochem Mol Morphol 2002; 10:210-217. (Pubitemid 34988527)
43. Zhao M, Zhang N-X, Economou M, et al.: Immunohistochemical detection of bcl-2 protein in liver lesions: Bcl-2 protein is expressed in hepatocellular carcinoma but not in liver cell dysplasia. Histopathology 1994; 25(3):237-245. (Pubitemid 24298434)
44. Kyokane K, Ito M, Ina K, Ando T, Kusugam K: Expression of bcl-2 2 p53 correlates with the morphology of gastric neoplasia. J Pathol. 1998; 184: 382-389. (Pubitemid 28179896)
45. Itoh T, Shiro T, Seki T, et al.: Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma. Int J. Mol. Med. 2000: 6(2): 137-142.
46. Duan XX, Ou JS, Li Y, et al.: Dynamic expression of apoptosis-related genes during development of laboratory hepatocellular carcinoma and its relation to apoptosis. World J Gastroenterol 2005; 11:4740-4744. (Pubitemid 41179534)
47. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inter-mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348:334-336. (Pubitemid 120029101)
48. Wu PC, Lau VK, Fang JW, et al.: Imbalance between cell proliferation and cellular DNA fragmentation in hepatocellular carcinomas. Liver 1999; 19(5): 444-451. (Pubitemid 29457225)
49. Chiu CT, Yeh TS, Hsu JC, Chen MF: Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocellular carcinoma. Dig. Dis. Sci. 2003; 48(4): 670-676. 50. Hemann MT, Lowe SW: News and commentary. The p53-Bcl-2 connection. Cell death and differentiation 2006; 13:1256-1259.